PCN11 The potential long-term comparative effectiveness of larotrectinib vs. lenvatinib or sorafenib for treatment of NTRK fusion-positive metastatic thyroid cancer
Abstract
Authors
J. Carlson K. Suh F. Xia T. Williamson S. Sullivan